These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 30104117

  • 1. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group.
    Vaccine; 2018 Sep 11; 36(38):5781-5788. PubMed ID: 30104117
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O.
    Hum Vaccin Immunother; 2018 Sep 11; 14(11):2624-2631. PubMed ID: 29902133
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.
    Nakayama T, Kawamura A, Sogawa Y, Sakakibara S, Nakatsu T, Kimata M, Oe K.
    J Infect Chemother; 2024 Dec 11; 30(12):1289-1294. PubMed ID: 38906375
    [Abstract] [Full Text] [Related]

  • 8. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.
    Pediatr Infect Dis J; 2005 Dec 11; 24(12):1083-8. PubMed ID: 16371870
    [Abstract] [Full Text] [Related]

  • 9. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J.
    Vaccine; 2017 May 25; 35(23):3116-3122. PubMed ID: 28457672
    [Abstract] [Full Text] [Related]

  • 10. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Groupa See Contributors section..
    Hum Vaccin Immunother; 2019 May 25; 15(4):786-799. PubMed ID: 30785357
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.
    Scand J Infect Dis; 2003 May 25; 35(10):736-42. PubMed ID: 14606613
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, Yamamura AM, Martins RM, Leal Mde L, Collaborative Group for the Study of Yellow Fever Vaccines.
    Vaccine; 2011 Aug 26; 29(37):6327-34. PubMed ID: 21640779
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S, Feyssaguet M, Povey M, Di Paolo E.
    Vaccine; 2019 Aug 23; 37(36):5323-5331. PubMed ID: 31345639
    [Abstract] [Full Text] [Related]

  • 17. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 18. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, Cryz SJ.
    Vaccine; 1998 Dec 13; 16(2-3):298-304. PubMed ID: 9607046
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T, Eda M, Hirano M, Goto W.
    Hum Vaccin Immunother; 2019 Dec 13; 15(5):1139-1144. PubMed ID: 30724658
    [Abstract] [Full Text] [Related]

  • 20. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
    Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL.
    J Pediatric Infect Dis Soc; 2015 Dec 13; 4(4):339-48. PubMed ID: 26582873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.